Fulcrum Therapeutics

169 articles about Fulcrum Therapeutics

• 

  Movers & Shakers, Jan. 7

  1/7/2022

  With the turn of the calendar, biopharma and life sciences organizations have bolstered their leadership teams and board with these Movers & Shakers.

• Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  1/7/2022

  Fulcrum Therapeutics, Inc. today announced the grant of an inducement award outside of the Company’s 2019 Stock Incentive Plan to Esther Rajavelu, the Company’s newly appointed Chief Financial Officer.

• Fulcrum Therapeutics® to Present at the 40th Annual J.P. Morgan Healthcare Conference

  1/6/2022

  Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that Bryan Stuart, President and Chief Executive Officer, will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 12:00 p.m. ET.

• 

  Clinical Catch-Up: December 6-10

  12/13/2021

  There were a lot of clinical trial announcements this week, driven by the European Society for Medical Oncology annual conference. Here’s a look.
• 

  BioSpace Movers & Shakers, Nov. 19

  11/19/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Fulcrum Therapeutics® Appoints Sonja L. Banks to its Board of Directors

  11/17/2021

  Fulcrum Therapeutics, Inc. today announced the appointment of Sonja L. Banks to the company’s board of directors, effective December 8.

• Fulcrum Therapeutics® Reports Recent Business Highlights and Third Quarter 2021 Financial Results

  11/4/2021

  Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, provided a business update and reported financial results for the third quarter of 2021.

• Fulcrum Therapeutics™ to Participate in Upcoming November 2021 Investor Conferences

  11/3/2021

  Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that management will be participating in the following upcoming investor conferences:

• Fulcrum Therapeutics™ to Host Third Quarter 2021 Financial Results Conference Call and Webcast on Thursday, November 4, 2021 at 8:00 a.m. ET

  10/28/2021

  Fulcrum Therapeutics, Inc. today announced that its third quarter 2021 financial results will be released on Thursday, November 4, 2021 before the U.S. financial markets open.

• Fulcrum Therapeutics™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Oct 01, 2021

  10/1/2021

  Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced the grant of an inducement award outside of the Company’s 2019 Stock Incentive Plan to Naomi Aoki, the Company’s newly appointed SVP, Communications and Investor Relations.

• 

  Clinical Catch-Up: September 20-24

  9/27/2021

  There was still some carryover from the European Society of Medical Oncology Congress 2021, but there was plenty of other clinical trial news last week. Here’s a look.

• Fulcrum Therapeutics™ Announces Multiple Presentations During the Virtual Congress of the World Muscle Society

  9/20/2021

  Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced it will present multiple posters and presentations on losmapimod for facioscapulohumeral muscular dystrophy during the Virtual Congress of the World Muscle Society.

• Fulcrum Therapeutics™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Sep 10, 2021

  9/10/2021

  Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced the grant of an inducement award outside of the Company’s 2019 Stock Incentive Plan to Mel Hayes, the Company’s newly appointed Chief Commercial Officer.

• 

  BioSpace Movers & Shakers, Sept. 10

  9/10/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Fulcrum Therapeutics™ Appoints Mel Hayes as Chief Commercial Officer

  9/8/2021

  Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced the appointment of Mel Hayes as Chief Commercial Officer, effective September 7, 2021.

• Fulcrum Therapeutics™ to Participate in Upcoming Investor Conferences in September 2021

  9/2/2021

  Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that management will be participating in the following upcoming investor conferences

• 

  Clinical Catch-Up: August 9-13

  8/16/2021

  There was plenty of clinical trial updates last week. Here’s a look.

• Fulcrum Therapeutics Announces Pricing of $125 Million Public Offering of Common Stock

  8/12/2021

  Fulcrum Therapeutics, Inc. announced that it has priced an underwritten public offering of 6,600,000 shares of its common stock at a public offering price of $19.00 per share, for total gross proceeds of approximately $125 million, before deducting underwriting discounts and commissions and offering expenses payable by Fulcrum.

• Fulcrum Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results

  8/10/2021

  Fulcrum Therapeutics, Inc. today provided a business update and reported financial results for the second quarter of 2021.

• Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock - Aug 10, 2021

  8/10/2021

  Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that it has commenced an underwritten public offering of $100 million of shares of its common stock.